RENFREW, Scotland – May 5, 2023 – Terumo Aortic, a division of Terumo Corporation, today announced that it has received FDA approval for an expanded indication of the RELAY®Pro Stent-graft System, now including dissection and transection in the United States.
This expanded indication allows physicians in the U.S. to use the RELAY Pro Stent-graft System to treat patients with aortic dissection and traumatic aortic transection, in addition to its previously approved indications, broadening treatment options for these complex conditions.
"This approval expands our ability to serve U.S. physicians treating patients with a broader range of aortic pathologies," said a Terumo Aortic representative. "We are committed to providing surgeons with versatile, reliable solutions for the treatment of complex aortic disease."
The RELAY Pro Stent-graft System is designed to treat a range of thoracic aortic diseases, and this expanded indication further strengthens its role as a comprehensive treatment option for physicians in the United States.
About Terumo Aortic
Terumo Aortic, a division of Terumo Corporation, designs, develops and manufactures a broad portfolio of stent-graft and surgical solutions for the treatment of aortic disease, serving physicians and patients worldwide.
